HEALTHEQUITY, INC.
No enriched coverage for $HQY in the last 7 days.
Moody’s upgraded HealthEquity, Inc. (NASDAQ:HQY) corporate family rating to Ba2 from Ba3 and raised its probability of default rating to Ba2-PD from Ba3-PD. It also upgraded $600 million senior unsecured notes to Ba3 from B1, with outlook changed to stable. Moody’s cited stronger operating cash flow and BenefitWallet integration, plus improved leverage and liquidity.
HEALTHEQUITY, INC. (HQY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. hqy-20260625 0001428336 false 0001428336 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) J
Fiore Michael Henry (EVP, CHIEF COMMERCIAL OFFICER) sold 3,142 shares of HEALTHEQUITY, INC. (HQY) at $95.00 ($0.30M total) on 2026-05-29 under a Rule 10b5-1 trading plan.
Recent HQY coverage spans insider activity, financial news and market movers.
In the last 30 days, HQY insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($224K). The most active reporter was Fiore Michael Henry, EVP, CHIEF COMMERCIAL OFFICER, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Higher credit ratings and improved leverage metrics should reduce perceived default risk and support bond/credit spreads, with potential spillover to equity sentiment.
The filing confirms shareholder approval of governance and equity compensation items, but provides no new financial guidance or operational change.
Insider selling is disclosed, but it is explicitly under a pre-arranged 10b5-1 plan, reducing signal strength.
Insider selling is a modest negative signal, but the filing specifies a pre-arranged 10b5-1 plan, reducing interpretive weight.
Insider selling disclosed for HQY; likely low signal given stated 10b5-1 pre-arranged plan, but it can still affect near-term sentiment.
alphai scores every news story that mentions HQY with an AI model for sentiment and relevance, and aggregates insider trades from HEALTHEQUITY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Moody’s upgraded HealthEquity, Inc. (NASDAQ:HQY) corporate family rating to Ba2 from Ba3 and raised its probability of default rating to Ba2-PD from Ba3-PD. It also upgraded $600 million senior unsecured notes to Ba3 from B1, with outlook changed to stable. Moody’s cited stronger operating cash flow and BenefitWallet integration, plus improved leverage and liquidity.
3 min readHEALTHEQUITY, INC. (HQY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. hqy-20260625 0001428336 false 0001428336 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) J
3 min readFiore Michael Henry (EVP, CHIEF COMMERCIAL OFFICER) sold 3,142 shares of HEALTHEQUITY, INC. (HQY) at $95.00 ($0.30M total) on 2026-05-29 under a Rule 10b5-1 trading plan.
2 min readWellborn Gayle Furgurson sold 2,439 shares of HEALTHEQUITY, INC. (HQY) at $90.00 ($0.22M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
2 min readLadd Delano (EVP, General Counsel) sold 7,500 shares of HEALTHEQUITY, INC. (HQY) at $90.00 ($0.68M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
2 min readCitizens Jmp raised its HealthEquity (NASDAQ: HQY) price target to $111 from $110 and reiterated a “market outperform” rating, citing about 22.14% upside from the stock’s level. Other analysts recently set targets ranging from $105 to $128. HealthEquity reported $1.24 EPS and $354.64M revenue in its May 28 quarter.
4 min readHealthEquity reported fiscal 2027 first-quarter results, citing 7% year-over-year revenue growth and a record adjusted EBITDA margin of 46%, according to the company. It raised guidance to $1.41–$1.42B revenue and $625–$633M adjusted EBITDA. The firm said it expanded digital engagement and Marketplace, used AI for efficiency, saw HSA assets +19% and new HSA sales +15%, and increased its share repurchase authorization by $1B.
6 min readHealthEquity, Inc. (NASDAQ:HQY) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 12-month price target of approximately $111.79. The company recently surpassed earnings per share and revenue expectations for its last quarter. Institutional investors hold a significant 99.55% of the stock.
3 min readB. Metzler seel. Sohn & Co. AG increased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 23.5% in the fourth quarter, now owning 104,078 shares valued at approximately $9.54 million. HealthEquity reported stronger-than-expected earnings and revenue in its latest quarter, prompting several analyst upgrades and a "Moderate Buy" consensus rating. The company's stock currently trades at $77.75, with a market capitalization of $6.57 billion.
2 min readHealthEquity announced the termination of its Chief Technology Officer and the consolidation of technology, product, and strategy leadership under Sunil Rajasekar. This organizational change is expected to influence how efficiently HealthEquity's tech investments, such as its AI-powered HSAnswers tool, translate into margin performance as the company pursues its digital transformation goals. Investors will be watching how this shift impacts cost control and operating leverage while monitoring potential increases in technology and fraud prevention spending.
4 min read
